Benitec Biopharma Company Insiders
BNTC Stock | USD 16.11 0.68 4.05% |
Benitec Biopharma's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Benitec Biopharma Ltd suggests that all insiders are extremely bullish. Benitec Biopharma employs about 16 people. The company is managed by 5 executives with a total tenure of roughly 22 years, averaging almost 4.0 years of service per executive, having 3.2 employees per reported executive.
Bryan Dulhunty Executive Chief Officer |
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
2024-12-23 | Suvretta Capital Management, L | Acquired 27502 @ 10.98 | View | ||
2024-12-03 | Suvretta Capital Management, L | Acquired 42000 @ 9.6 | View |
Monitoring Benitec Biopharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Benitec |
Benitec Biopharma's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Benitec Biopharma's future performance. Based on our forecasts, it is anticipated that Benitec will maintain a workforce of about 16 employees by April 2025.Benitec Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.496) % which means that it has lost $0.496 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9168) %, meaning that it created substantial loss on money invested by shareholders. Benitec Biopharma's management efficiency ratios could be used to measure how well Benitec Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.57. At present, Benitec Biopharma's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 147.3 K, whereas Non Current Assets Total are forecasted to decline to about 583.5 K.The current year's Common Stock Shares Outstanding is expected to grow to about 4.9 M, whereas Net Loss is forecasted to decline to (18.5 M).
Benitec Biopharma Workforce Comparison
Benitec Biopharma Ltd is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 371. Benitec Biopharma holds roughly 16.0 in number of employees claiming about 4% of equities under Health Care industry.
Benitec Biopharma Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Benitec Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Benitec Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Benitec Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 1.0 | 2 | 2 | 155,439 | 155,439 |
2024-09-01 | 1.25 | 5 | 4 | 7,137,763 | 11,944,527 |
Benitec Biopharma Notable Stakeholders
A Benitec Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Benitec Biopharma often face trade-offs trying to please all of them. Benitec Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Benitec Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Graham | Founding Scientist and Head of Discovery | Profile | |
Bryan Dulhunty | Chief Officer | Profile | |
Sophie Mukadam | Chief Officer | Profile | |
Claudia Kloth | Senior Manufacturing | Profile | |
Craig Lewis | Chief Adviser | Profile |
About Benitec Biopharma Management Performance
The success or failure of an entity such as Benitec Biopharma often depends on how effective the management is. Benitec Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Benitec management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Benitec management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.48) | (0.50) | |
Return On Capital Employed | (0.55) | (0.57) | |
Return On Assets | (0.48) | (0.50) | |
Return On Equity | (0.53) | (0.56) |
Please note, the presentation of Benitec Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Benitec Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Benitec Biopharma's management manipulating its earnings.
Benitec Biopharma Workforce Analysis
Traditionally, organizations such as Benitec Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Benitec Biopharma within its industry.Benitec Biopharma Manpower Efficiency
Return on Benitec Biopharma Manpower
Revenue Per Employee | 13.5K | |
Revenue Per Executive | 43.2K | |
Net Loss Per Employee | 1.4M | |
Net Loss Per Executive | 4.4M | |
Working Capital Per Employee | 2.9M | |
Working Capital Per Executive | 9.3M |
Complementary Tools for Benitec Stock analysis
When running Benitec Biopharma's price analysis, check to measure Benitec Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Benitec Biopharma is operating at the current time. Most of Benitec Biopharma's value examination focuses on studying past and present price action to predict the probability of Benitec Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Benitec Biopharma's price. Additionally, you may evaluate how the addition of Benitec Biopharma to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |